Celebrex Gets Thumbs Up For Kids, But Cmte. Wants Follow-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee urges Pfizer to create an active surveillance program to track potential safety issues from the use of the COX-2 inhibitor for juvenile rheumatoid arthritis.
You may also be interested in...
Celebrex-mas: Pfizer Gets Early Present With Juvenile RA Approval
Firm will have to conduct a long-term registry to further evaluate safety concerns with the COX-2 inhibitor, including cardiovascular events.
Celebrex-mas: Pfizer Gets Early Present With Juvenile RA Approval
Firm will have to conduct a long-term registry to further evaluate safety concerns with the COX-2 inhibitor, including cardiovascular events.
Celebrex JRA Indication To Be Evaluated By FDA Advisory Committee
Lack of long-term safety data “poses a special challenge” in weighing risks and benefits, FDA says in briefing documents.